Application of herba epimedii and poria cocos granulation-promoting granules in treatment of amyotrophic lateral sclerosis

Huoling Shengji Granules prepared by water extraction, steam concentration and granulation processes of traditional Chinese medicine compositions solved the problem of poor ALS treatment effect, significantly improved the functional evaluation scale score and survival of ALS patients, especially for non-family Patients and rapid progressive cases have significant efficacy.

CN119015350APending Publication Date: 2024-11-26SHANGHAI SPH RARE DISEASE PHARMA CO LTD

Patent Information

Application Number
CN202411115969.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Amyotrophic lateral sclerosis (ALS) is still an incurable disease, and existing treatments cannot fully meet the survival improvement needs of non-family patients, especially for patients with rapid progress and severe cases, with existing drug treatments. Limited effect.

Method used

A Chinese medicine composition, including epimedium, Rehmannia glutinosa, Cornus officinalis, Astragalus, fried Atractylodes and Poria cocos, was prepared into granules by water extraction, steam concentration, drying and granulation, and was used for oral treatment of ALS. , significantly improves muscle weakness, motor function and respiratory function, and prolongs survival.

Benefits of technology

It significantly improves the functional assessment scale score of patients with ALS and prolongs survival, especially for non-family patients and rapidly progressive cases. It is better than the existing positive control drug riluzole, which significantly improves the quality of life of patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004993625510000091
    Figure BDA0004993625510000091
  • Figure BDA0004993625510000101
    Figure BDA0004993625510000101
  • Figure BDA0004993625510000111
    Figure BDA0004993625510000111
Patent Text Reader

Abstract

The invention provides an application of herba epimedii and poria cocos granulation promoting granules in treatment of amyotrophic lateral sclerosis, and particularly provides an application of a traditional Chinese medicine composition in preparation of a pharmaceutical composition or a pharmaceutical combination for treating amyotrophic lateral sclerosis (ALS). The traditional Chinese medicine composition is prepared from the following components in parts by weight: 60 to 130 parts of herba epimedii, 60 to 150 parts of radix rehmanniae recen, 60 to 100 parts of wine-prepared fructus corni, 90 to 150 parts of radix astragali seu hedysari, 40 to 110 parts of rhizoma atractylodis macrocephalae stir-fried with bran and 30 to 90 parts of poria cocos. The amyotrophic lateral sclerosis is non-family type amyotrophic lateral sclerosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of traditional Chinese medicine, and in particular, relates to use of Huoling Shengji granules for treating amyotrophic lateral sclerosis. Background Art

[0002] Amyotrophic lateral sclerosis (ALS), commonly known as "Lou Gehrig's disease", is a rare neurodegenerative disease that affects the cerebral cortex, brainstem and spinal motor neurons. Clinical manifestations include muscle weakness, muscle atrophy, bulbar paralysis and pyramidal tract signs, and eventually respiratory failure due to respiratory muscle weakness. It usually develops in middle-aged and elderly people, and the patient's survival period is usually 3-5 years. It has the characteristics of insidious onset, rapid progression, disability and death.

[0003] About 90%-95% of patients have sporadic amyotrophic lateral sclerosis (sALS), and the remaining 5%-10% have familial amyotrophic lateral sclerosis (fALS), which is mostly autosomal dominant 2. The discovery of ALS-related genes began with the SOD1 gene in 1993. Advances in genetic technology have enabled us to gradually discover more pathogenic genes related to ALS, such as TDP-43, C9ORF72, FUS, ATAX2, etc. 3, 4, 5. Other possible pathogenesis includes abnormal RNA processing, glutamate excitotoxicity, cytoskeletal disorder, mitochondrial dysfunction, viral infection, apoptosis, abnormal growth factors, inflammatory response, etc.

[0004] ALS is still an incurable disease, and the focus of treatment is to maximize the patient's quality of life. So far, the FDA has only approved three therapeutic drugs (riluzole, edaravone and Qalsody). In addition to the above drugs, various new therapies are also in full swing, such as AAV gene therapy, Treg cell therapy, and antibody therapy are all progressing steadily. However, the above approved drugs still cannot fully meet the treatment needs, especially for non-familial patients, the degree of survival improvement is still limited. Summary of the invention

[0005] The object of the present invention is to provide a use of a traditional Chinese medicine composition for preparing a pharmaceutical composition or a pharmaceutical combination for treating amyotrophic lateral sclerosis (ALS).

[0006] The first aspect of the present invention provides a use of a Chinese medicine composition for preparing a pharmaceutical composition or a pharmaceutical combination for treating amyotrophic lateral sclerosis (ALS), wherein the Chinese medicine composition comprises:

[0007] 60-130 weight parts of epimedium, 60-150 weight parts of raw rehmannia, 60-100 weight parts of cornus fruit cooked with wine, 90-150 weight parts of astragalus, 40-110 weight parts of stir-fried atractylodes macrocephala with bran, and 30-90 weight parts of poria; preferably, the traditional Chinese medicine composition comprises: 70-90 weight parts of epimedium, 80-120 weight parts of raw rehmannia, 80-90 weight parts of cornus fruit cooked with wine, 120-130 weight parts of astragalus, 70-80 weight parts of stir-fried atractylodes macrocephala with bran, and 70-80 weight parts of poria.

[0008] In another preferred embodiment, the ALS is non-familial ALS.

[0009] In another preferred embodiment, the Chinese medicine composition is an oral preparation; preferably a granule.

[0010] In another preferred embodiment, the Chinese medicine composition is prepared by the following method:

[0011] (a) extracting the mixture of the raw materials with water to obtain a water extract juice;

[0012] (b) steam concentrating the medicinal juice to obtain a concentrated product;

[0013] (c) drying the concentrated product to obtain a dry extract;

[0014] (d) mixing the dry extract with an excipient and granulating the mixture to obtain the Chinese medicine composition granules.

[0015] In another preferred embodiment, in the step (a), the water extraction comprises: boiling the mixture of the various raw materials with water to obtain the water-extracted medicinal juice.

[0016] In another preferred embodiment, in the step (b), the steam concentration is carried out at a steam pressure of less than 0.3 MPa; preferably at -0.01-0.3 MPa.

[0017] In another preferred embodiment, in the step (b), the steam concentration is carried out at a vacuum degree of -0.01 MPa to 0.1 MPa.

[0018] In another preferred embodiment, in the step (b), the relative density of the concentrated product is 1.10 to 1.45.

[0019] In another preferred embodiment, in the step (c), the drying is carried out at a steam pressure of 0.10-0.30 MPa.

[0020] In another preferred embodiment, in the step (c), the drying is performed at a vacuum degree of -0.04 to 0.1 MPa.

[0021] In another preferred embodiment, in the step (c), the drying is carried out at 20-100°C.

[0022] In another preferred embodiment, in step (d), the excipient is selected from the following group: sucralose, magnesium stearate, dextrin, or a combination thereof.

[0023] In another preferred embodiment, the pharmaceutical composition is used to improve the disease state of patients with amyotrophic lateral sclerosis.

[0024] In another preferred embodiment, the improvement of the disease state includes improvement of one or more indicators selected from the following group:

[0025] (i) The decrease in the modified Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score from baseline was reduced;

[0026] (ii) improve the patient's medullary function;

[0027] (iii) improve patients’ gross motor function;

[0028] (iv) Improve patients’ fine motor function;

[0029] (v) Improve the patient's respiratory function;

[0030] (vi) The patients’ survival time is prolonged.

[0031] In another preferred embodiment, the prolonged survival of the patient means that the survival of the patient is prolonged by 5-6 months compared with the case of using riluzole.

[0032] In another preferred embodiment, the patient is a patient in stage I, stage II or stage III in King staging.

[0033] In another preferred embodiment, the patient is a patient with a fast disease progression rate (disease progression rate > 0.3 points / month).

[0034] In another preferred embodiment, the patient is under 65 years old.

[0035] In another preferred embodiment, the patient is a patient with FVC%≥80%.

[0036] In another preferred embodiment, the patient is a patient who is clinically likely to suffer from ALS-laboratory supported.

[0037] In another preferred embodiment, the patient is a female patient.

[0038] In another preferred embodiment, the pharmaceutical composition is used to improve ALS-related symptoms in patients who have not responded well to other drug treatments; preferably, the other drugs are riluzole and / or edaravone.

[0039] In another preferred embodiment, the patient is a patient who has used the Chinese medicine composition.

[0040] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] Figure 1 Flowchart for subject distribution;

[0042] Figure 2 The subgroup analysis results of the primary efficacy indicator (mITT); mean difference represents the least square mean difference of the change of ALSFRS-R score compared with the baseline between the Huoling Shengji Granule treatment group and the riluzole treatment group after 48 weeks of treatment, in points.

[0043] Figure 3 Results were analyzed for different functional domains of ALSFRS-R scores. DETAILED DESCRIPTION

[0044] After long-term and in-depth research, the inventor unexpectedly found that Huoling Shengji Granule can effectively improve the disease progression of patients with amyotrophic lateral sclerosis, especially non-familial amyotrophic lateral sclerosis patients, and its effect is better than that of the positive control drug. Based on the above findings, the inventor completed the present invention.

[0045] Use of Huoling Shengji Granules for treating amyotrophic lateral sclerosis

[0046] The prescription of Huoling Shengji Granules is derived from clinical experience. It is mainly used to treat diseases such as muscle atrophy, limb weakness, muscle tremors caused by damage to essence and qi, deficiency of qi and blood, insufficiency of internal organs, and malnutrition of meridians and muscles.

[0047] Huoling Shengji Granules (HLSJ) are prepared by extracting epimedium, astragalus, cornus officinalis, bran-fried atractylodes, radix rehmanniae, and poria. Studies have shown that HLSJ granules contain a variety of different active ingredients from different Chinese medicinal materials. However, studies have shown that a single active ingredient of Chinese medicine cannot be used to treat ALS, because no improvement effect is observed for many symptoms such as muscle weakness in ALS. In addition, before the present invention, there has been no research and report on the use of HLSJ granules for the treatment of non-familial ALS.

[0048] The inventors found that HLSJ (18.9 or 25.2 g / kg / d) can significantly prolong the survival time of SOD1G93A mice, similar to riluzole (30 mg / kg / d). Unexpectedly, HLSJ granules can significantly improve symptoms such as myasthenia in ALS patients, including significant improvement in gross motor function, significant improvement in fine motor function, and significant improvement in respiratory function, thereby significantly improving the survival of patients.

[0049] The inventors analyzed and studied clinical data for more than 10 years and unexpectedly found that HLSJ can not only slow down the progression of ALS to a certain extent, but also improve the patient's symptoms, such as shortness of breath, spontaneous sweating, dry throat, irritability, tinnitus, back and knee pain, etc., and has certain advantages in the treatment of ALS. Based on the results of the above animal model and human experience, HLSJ was used to delay the progression of ALS and compared with riluzole.

[0050] As the active ingredient of the present invention, the Huoling Shengji Granules are mainly made of the following raw materials in parts by weight: 2-5 parts of Epimedium, 1-3 parts of Atractylodes macrocephala stir-fried with bran, and 1-3 parts of Poria; preferably, the above-mentioned Huoling Shengji Granules are mainly made of the following raw materials in parts by weight: 2-4 parts of Epimedium, 1-2 parts of Atractylodes macrocephala stir-fried with bran, and 1-2 parts of Poria.

[0051] In some preferred embodiments, other drugs can be added on the basis of the above-mentioned three Chinese medicines of Epimedium, Atractylodes macrocephala and Poria, for example, one or more drugs selected from the following group: 2-6 parts of Astragalus, 2-6 parts of Codonopsis pilosula, 1-4 parts of Cornus officinalis, 1-4 parts of Schisandra chinensis, 2-4 parts of Rehmannia root and 2-4 parts of Paeonia suffruticosa.

[0052] In the most preferred embodiment of the present invention, the Huoling Shengji Granules include: Epimedium

[0053] 70-90 weight parts of epimedium, 80-120 weight parts of raw rehmannia, 80-90 weight parts of cornus fruit cooked with wine, 120-130 weight parts of astragalus, 70-80 weight parts of stir-fried atractylodes with bran, and 70-80 weight parts of poria.

[0054] However, it should be understood that other similar formulations can also achieve similar effects to the present invention to varying degrees.

[0055] The compound of the present invention can be prepared by conventional methods of Chinese medicine preparations, for example, decocting the raw medicine in water, or extracting it with an alcohol-water mixture, and then concentrating and drying the decoction or extract to make a dry extract powder, adding appropriate excipients to the extract powder and the medicine, and preparing it into a Chinese medicine oral granule preparation by conventional pharmaceutical methods of those skilled in the art. In the most preferred embodiment of the present invention, the Chinese medicine composition is prepared by the following method:

[0056] (a) extracting the mixture of the raw materials with water to obtain a water extract juice;

[0057] (b) steam concentrating the medicinal juice to obtain a concentrated product;

[0058] (c) drying the concentrated product to obtain a dry extract;

[0059] (d) mixing the dry extract with an excipient and granulating the mixture to obtain the Chinese medicine composition granules.

[0060] The main advantages of the present invention include:

[0061] (a) The present invention provides a new drug (Huo Ling Sheng Ji Granule) for treating ALS with clinical value and a treatment method.

[0062] (b) The present invention can not only improve the symptoms of myasthenia gravis and significantly increase limb strength, but also significantly delay the progression of muscle atrophy. In particular, for patients with non-familial amyotrophic lateral sclerosis of unknown etiology, the efficacy is better than that of clinical positive control drugs.

[0063] (c) The therapy of the present invention has a significant therapeutic effect and particularly significant benefits for patients under 65 years of age (although such patients have a faster onset or more severe disease course).

[0064] (d) For patients who have poor drug treatment effects or have been treated with clinical drugs (such as riluzole and / or edaravone), the present invention also has obvious therapeutic effects and can significantly improve various related symptoms of amyotrophic lateral sclerosis.

[0065] (e) The drug or treatment of the present invention can significantly prolong the survival period, and the effect is better than the current clinical positive control drug.

[0066] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.

[0067] Embodiment 1 Huoling Shengji Granule Process

[0068] 1. Decoction

[0069] Add 70kg each of Epimedium and Rehmannia root, 85kg of Cornus officinalis, 125kg of Astragalus, 75kg of Atractylodes macrocephala stir-fried with bran, and 80kg of Poria to water and boil twice. Add water to extract (extract twice) and combine the two medicinal juices for later use.

[0070] 2. Concentration

[0071] The secondary medicine juice is concentrated to a relative density of 1.10 to 1.45 to obtain a concentrated solution.

[0072] 3. Filter

[0073] The 2 concentrated medicinal solutions were filtered to obtain an extract.

[0074] 4. Drying and crushing

[0075] Drying: Spread the concentrated extract into a stainless steel plate and dry it in a vacuum drying equipment. The steam pressure is controlled at ≤0.30Pa. When the vacuum degree is above -0.04-0.1Mpa, heating can be turned on. The temperature can be adjusted appropriately according to the material conditions. After drying (the moisture content should not exceed 8.0%), turn off the heating and vacuum.

[0076] Crushing: slowly add the dry extract powder into the grinder and crush it. The dry extract powder is obtained by crushing.

[0077] 5. Premixing, granulation, and total mixing

[0078] Premixing: Add sucralose, magnesium stearate and dextrin to the dry extract powder at a speed of 10 rpm for 5-25 minutes.

[0079] Granulation operation: Install the screen, add the granules to the dry granulator, start the equipment for granulation according to the standard operating procedures of the dry granulator, feed speed 20-30rpm, roller speed 6-18Rpm, oil pressure 70-160bar, granulation speed 100-140rpm. Pour the granulated granules into the oscillating screen to collect fine powder (fine particles that can pass through the bottom 80 mesh screen) and coarse particles (coarse particles that cannot pass through the top 30 mesh screen). Re-granulate the collected fine powder and re-granulate.

[0080] Total mixing: the granules obtained by the dry method are mixed again at a speed of 10 rpm for 5 minutes.

[0081] 6. Internal packaging

[0082] Use composite film for pharmaceutical packaging, adjust the temperature, the vertical sealing temperature is 120-150°C, the horizontal sealing temperature is 140-190°C, after preheating, adjust the filling amount to the filling amount difference of 20g±4% for internal packaging.

[0083] The prepared Chinese medicine granules were used in the following experiments.

[0084] Example 2 Clinical study of HLSJ for the treatment of ALS

[0085] Study Design and Oversight

[0086] The clinical study of Huoling Shengji Granule for the treatment of ALS adopted a randomized, double-blind, double-dummy, positive-controlled superiority trial design and was conducted in 11 clinical centers in China. Patients who met all the inclusion criteria and did not meet the exclusion criteria were randomly assigned to the experimental group and the control group in a 1:1 ratio for intervention and evaluation. The trial was divided into two phases with a total duration of approximately 49 weeks:

[0087] The baseline period was up to 1 week, and the treatment period was 48 weeks. The ethical approval procedure was authorized by the ethics committee of each clinical trial institution and was conducted in full compliance with the current ethical standards of human medical research in the Declaration of Helsinki. The relevant data were monitored by an independent data monitoring committee.

[0088] Study population

[0089] Patients aged between 45 and 70 years, meeting the ALS diagnostic criteria (confirmed, suspected or suspected laboratory support), normal ALSFRS-R respiratory function score, other scores of 2 points or above, FVC% of 70% or above, disease course of 3 years or less (from the first appearance of any symptoms of ALS), diagnosed with non-familial ALS, TCM syndrome differentiation of Qi deficiency and kidney yang deficiency, and willing to participate in this clinical trial and sign the informed consent form, are eligible for inclusion. For detailed exclusion criteria, please refer to previously published literature. The researchers ensure that each patient voluntarily provides informed consent before entering the trial, and obtain written informed consent after the patient (or his / her guardian) and the researcher sign it.

[0090] Randomization, Blinding, and Procedure

[0091] This trial used block randomization. After selecting the appropriate block size, an independent statistician generated a random sequence of 144 subjects (experimental group and control group) in a 1:1 ratio in SAS version 9.4 (SASInstitute) and listed the random table of this study for import into the interactive web response system. Patients were randomly assigned to receive HLSJ or riluzole treatment with equal opportunities without stratification. The trial was blinded to both investigators and participants by the application of sham agents and the uniformity of drug packaging. After randomization, patients were given HLSJ (20 g) + riluzole placebo or riluzole tablets (50 mg) + HLSJ placebo twice a day for 48 weeks. During this period, 4 visits were conducted at 12, 24, 36, and 48 weeks after the start of medication.

[0092] result

[0093] The primary outcome measure was the change in ALSFRS-R score from baseline after 48 weeks of treatment. Secondary outcomes included the change in ALSFRS-R score from baseline after 12, 24, and 36 weeks of treatment; the change in ROADS score, ALSAQ-40 score, TCM syndrome score, and FVC% from baseline after 12, 24, 36, and 48 weeks of treatment; and the incidence and time of endpoint events (death, tracheotomy, or persistent ventilator dependence) after treatment.

[0094] Sample size

[0095] According to literature reports and expert discussions, the experimental group improved by 2 points (μ T -μ C =2), combined standard deviation S = 4.0; α = 0.05 (bilateral), β = 0.20, power = 0.80, the experimental group and the control group were allocated at a ratio of 1:1, and the statistical sample size was 64 cases in each group, totaling 128 cases. Considering the dropout / removal rate of 10%, the proposed trial included 72 subjects in the experimental group and 72 subjects in the control group, totaling 144 cases.

[0096] Statistical analysis

[0097] The modified Intention to Treat Set (mITT) was based on the intention-to-treat principle and included all patients who were randomized and received at least one trial drug treatment and had post-drug evaluation data as the primary efficacy analysis set. To study safety characteristics, the safety analysis set (SS) included all patients who received at least one trial drug and had post-drug safety evaluation data recorded.

[0098] Mixed-effect models for Repeated Measures (MMRM) were used to evaluate the primary outcome. The ALSFRS-R score at each visit was used as the dependent variable. The baseline covariates of age stratification (not required for mITT), ALS diagnosis type, visit time, treatment group, and visit time × treatment group interaction were included. The least squares mean (LSMEAN) and its 95% CI were α-corrected confidence intervals were calculated. The experimental group was considered to be superior to the control group when the P value of the group effect test was less than 0.049 and the lower limit of the α-corrected confidence interval of the difference between the least squares mean of the experimental group and the control group was greater than zero. Subgroup analyses related to clinical stratification (e.g., medullary and non-medullary) were performed in the same way.

[0099] In the safety analysis, all adverse events (AEs) occurring during the period were summarized according to system organ class and preferred terminology and analyzed using χ 2The incidence of AEs or adverse reactions between the groups was compared using the statin test or Fisher's exact test.

[0100] No missing values ​​were imputed for primary, secondary, and safety variables. Statistical analyses were performed using SAS, version 9.4 (SAS Institute). In all statistical analyses, two-sided tests were considered statistically significant with a P value of <0.049.

[0101] Subjects

[0102] Between July 22, 2021 and May 26, 2022, a total of 144 patients were enrolled in 11 hospitals in China. Among them, 1 patient was randomly excluded because he did not meet the inclusion criteria, and the remaining 143 patients (71 in the HLSJ group and 72 in the riluzole group) received medical intervention and were included in the SS. 128 patients (64 in the HLSJ group and 64 in the riluzole group) were included in the mITT ( Figure 1 ).

[0103] The mean age of patients receiving HLSJ was 53.4 years (SD, 5.61) and the mean baseline ALSFRS-R total score was 42.5 (SD, 2.42), while the mean age of patients in the riluzole group was 55.6 years (SD, 5.63) and the mean baseline ALSFRS-R total score was 42.4 (SD, 2.34).

[0104] The baseline demographic and clinical characteristics of the study population were well-distributed ( Table 1 ).

[0105] Table 1. Baseline demographic and clinical characteristics of the study population (mITT)

[0106]

[0107]

[0108] Abbreviations: ALS, amyotrophic lateral sclerosis; ALSAQ-40, amyotrophic lateral sclerosis self-assessment questionnaire-40; ALSFRS-R, modified amyotrophic lateral sclerosis functional rating scale; FVC, forced vital capacity; ROADS, Rasch global disability rating scale for amyotrophic lateral sclerosis; TCM, traditional Chinese medicine; WFN, World Federation of Neurology.

[0109] a It is calculated as body weight (kg) divided by height (m) squared.

[0110] bAccording to El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral published by the WFN research group in 2000, there are 4 types: confirmed diagnosis, suspected diagnosis, suspected diagnosis with laboratory support, and possible diagnosis.

[0111] c Calculated as the date of randomization minus the date of first symptom onset.

[0112] d Ca was calculated as 48 minus the baseline ALSFRS-R total score and divided by the disease duration (months).

[0113] e It is formulated based on the "Traditional Chinese Medicine Diagnosis and Treatment Plan for Paralysis (Motor Neuron Disease)" issued by the China Association of Traditional Chinese Medicine in 2018.

[0114] Efficacy Outcomes

[0115] The LSMEAN (95% CI) of the change of ALSFRS-R score from baseline in the HLSJ group and the riluzole group after 48 weeks of treatment were -10.25 (-11.24 to -9.26) and -12.55 (-13.52 to -11.58), respectively. The difference between the two groups was calculated by the Mixed-effect Models for Repeated Measures (MMRM) and was 2.88 (1.02 to 4.73, P = 0.0025), indicating that after 48 weeks of treatment, Huoling Shengji Granules could reduce the ALSFRS-R score by 2.88 points compared with riluzole, and the difference was statistically significant.

[0116] In patients with rapidly progressive disease (dichotomized), the LSMEAN difference was 2.68 (95% CI, 0.39-4.97; P = 0.022).

[0117] Subgroup analysis also showed that the HLSJ effect was statistically significant compared with riluzole in subgroups of patients with FVC% ≥ 80%, patients with clinically probable ALS-laboratory support, and female patients ( Figure 2 ).

[0118] The ALSFRS-R score includes 12 sub-items, which can be divided into four functional domains: fine movements (fine motor function), large muscle movements (gross motor function), medullary (brain) function, and respiratory function.

[0119] Analysis of the functional domains showed that Huoling Shengji Granules had a certain positive effect on all four functional domains compared with riluzole. Especially in the respiratory function domain and fine motor domain, Huoling Shengji Granules had significant differences compared with riluzole: the difference between the respiratory function domain score and the fine motor score was 0.54 (95CI% 0.06-1.02), P = 0.0269, and the difference between the fine motor score and the respiratory function domain was 1.03 (95CI% 0.05-2.00), P = 0.0387, indicating that Huoling Shengji Granules had a better effect on improving the respiratory function and fine motor function of ALS patients than riluzole ( Figure 3 ).

[0120] Safety Outcomes

[0121] A total of 232 AEs were reported by 57 patients (80.28%) in the HLSJ group, and a total of 225 AEs were reported by 58 patients (80.56%) in the riluzole group, with no significant difference between the two groups (P=0.9671). The number and percentage of patients with AEs did not show any significant differences between the groups, regardless of the level of severity or the degree of relevance to the trial drug. Six patients died, five of whom were caused by ALS disease progression and its complications, and the remaining one was caused by COVID-19, which had no causal relationship with the trial drug. No adverse reactions of grade 3 or above, serious adverse reactions, or adverse reactions leading to death occurred in the HLSJ group. In terms of laboratory tests, there were no hematological-related adverse reactions, and no cases of severe liver and kidney injury occurred in the HLSJ group. Mild effects on the liver and kidneys are tolerable and do not affect drug compliance. One patient with a history of coronary atherosclerosis who received HLSJ treatment experienced a cardiac-related adverse event (abnormal electrocardiogram T wave, 1.41%), which did not affect the trial drug treatment and recovered naturally.

[0122] Table 2. Safety analysis of Huoling Shengji and riluzole groups during the randomized controlled period (safety analysis set)

[0123]

[0124] Abbreviations: TEAE, treatment-emergent adverse event.

[0125] a If multiple cases of the same adverse event occur in the same subject, the severity level or relevant category of the adverse event in the subject is counted only once, but the number of events is counted according to the actual number of occurrences. If the severity or causal relationship of these same adverse events is different, they are counted once in the most serious or most relevant category.

[0126] b Calculated based on the number of subjects in each group.

[0127] cAdverse events were recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0, with a grade of 1-5.

[0128] Summarize

[0129] This multicenter clinical trial evaluated the effectiveness and safety of Huoling Shengji Granules in the treatment of amyotrophic lateral sclerosis (spleen deficiency and kidney yang deficiency syndrome) compared with riluzole. The results showed that Huoling Shengji Granules showed clinical efficacy in ALS patients. The efficacy evaluation indicators used multiple internationally recognized functional evaluation scales, showing that it has the effect of improving patients' functional disorders, quality of life, etc.

[0130] The research of the present invention shows that the drug of the present invention is significantly superior to the first-line clinical drug riluzole in improving functional impairment. The research shows that for every 16.5% decrease in the ALSFRS-R decline rate, the median survival period is correspondingly extended by 4-5 months. Considering that in people aged less than or equal to 65 years old, HLSJ slows down the decrease of ALSFRS-R by 23% (2.88÷12.5×100%=23%) compared with riluzole, the above results suggest that HLSJ can further extend the median survival period by 5.7-7.1 months compared with riluzole.

[0131] In addition, a multicenter clinical study found for the first time that Huoling Shengji Granules has a particularly significant clinical therapeutic effect on ALS patients who are clinically diagnosed with ALS, have a history of edaravone treatment, have the onset of the disease located in the bulb, have a pulmonary function test score of FVC% less than 80%, and have rapid disease progression (disease progression rate >0.3 points / month).

[0132] The above research results fully highlight the therapeutic advantages and value of the Huoling Shengji Granules of the present invention for amyotrophic lateral sclerosis, and it has good safety for long-term use. It is an innovative, groundbreaking and exemplary new Chinese medicine variety.

[0133] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A Chinese medicine composition for preparing a pharmaceutical composition or a pharmaceutical combination for treating amyotrophic lateral sclerosis (ALS), wherein the Chinese medicine composition include: 60-130 weight parts of epimedium, 60-150 weight parts of raw rehmannia, 60-100 weight parts of cornus fruit cooked with wine, 90-150 weight parts of astragalus, 40-110 weight parts of stir-fried atractylodes macrocephala with bran, and 30-90 weight parts of poria; preferably, the traditional Chinese medicine composition comprises: 70-90 weight parts of epimedium, 80-120 weight parts of raw rehmannia, 80-90 weight parts of cornus fruit cooked with wine, 120-130 weight parts of astragalus, 70-80 weight parts of stir-fried atractylodes macrocephala with bran, and 70-80 weight parts of poria.

2. The use according to claim 1, It is characterized in that The amyotrophic lateral sclerosis described is non-familial amyotrophic lateral sclerosis.

3. The use according to claim 1, It is characterized in that The Chinese medicine composition is an oral preparation; preferably a granule.

4. The use according to claim 1, It is characterized in that The Chinese medicine composition is prepared by the following method: (a) extracting the mixture of the raw materials with water to obtain a water extract juice; (b) steam concentrating the medicinal juice to obtain a concentrated product; (c) drying the concentrated product to obtain a dry extract; (d) mixing the dry extract with an excipient and granulating the mixture to obtain the Chinese medicine composition granules.

5. The use according to claim 1, It is characterized in that The pharmaceutical composition is used for improving the disease state of patients with amyotrophic lateral sclerosis.

6. The use according to claim 5, It is characterized in that The improvement of the disease state includes improvement of one or more indicators selected from the following group: (i) The decrease in the modified Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score from baseline was reduced; (ii) improve the patient's medullary function; (iii) improve patients’ gross motor function; (iv) Improve patients’ fine motor function; (v) Improve the patient's respiratory function; (vi) The patients’ survival time is prolonged.

7. The use according to claim 5, It is characterized in that The patients are patients with stage I, stage II or stage III in King staging.

8. The use according to claim 5, It is characterized in that The patients are patients with rapid disease progression rate (disease progression rate>0.3 points / month).

9. The use according to claim 5, It is characterized in that The patients described are patients under 65 years old.

10. The use according to claim 5, It is characterized in that The pharmaceutical composition is used to improve the symptoms related to amyotrophic lateral sclerosis in patients who have not responded well to other drug treatments; preferably, the other drugs are riluzole and / or edaravone.

Citation Information

Patent Citations

  • Traditional Chinese medicine composition for treating amyotrophic lateral sclerosis and preparation method thereof

    CN104825525A

  • Application of traditional Chinese medicine composition in preparation of medicine for treating spinal muscular atrophy and preparation method of traditional Chinese medicine composition

    CN116115684A

  • Application of traditional Chinese medicine composition in preparation of medicine for treating sarcopenia and preparation method of traditional Chinese medicine composition

    CN116115685A

Cited By

  • Use of huolingshengji keli granules for treatment of amyotrophic lateral sclerosis

    WO2026037187A1